HALLE (SALLE), Germany—June 11 saw the official switch of Probiodrug AG’s company name to Vivoryon Therapeutics AG. The company will continue its focus on finding therapeutic solutions for Alzheimer’s disease, and PQ912, its lead molecule, will be moving into two clinical Phase 2b trials in Europe and the United States for the treatment of Alzheimer’s disease.

 

“Vivoryon, composed of ‘Vivid Memory On,’ expresses our strong commitment to develop a transformational therapeutic option for patients with Alzheimer’s disease against the backdrop of multiple late-stage industry disappointments. With our proprietary Glutaminyl cyclase inhibition platform, we are technology leaders in this field which has also opened up new opportunities to bring scientific excellence for the benefit of patients to other indications, as we currently see in immuno-oncology,” said Dr. Ulrich Dauer, CEO of Vivoryon Therapeutics.